Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00061035 |
Recruitment Status :
Completed
First Posted : May 22, 2003
Last Update Posted : August 28, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostatic Neoplasms | Biological: Transgenic Lymphocyte Immunization Vaccine (TLI) | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 18 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma |
Study Start Date : | April 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older, able to understand and sign the informed consent form.
- HLA-A2 positive.
- Expected survival ≥ 6 months.
- Histological evidence of adenocarcinoma of the prostate.
- (ECOG) Performance status 0, 1 or 2.
The following categories of subjects with androgen-independent prostate cancer are eligible:
- Progression of bidimensionally measurable disease assessed within 84 days (12 weeks) prior to enrollment.
- Progression of evaluable but not measurable disease (i.e., bone scan) assessed within 112 days (16 weeks) prior to enrollment.
- Rising PSA- Rising PSA is defined as at least two consecutive rises in PSA to be documented over a reference value (measure 1). The first rising PSA (measure 2) must be taken at least 7 days after the reference value. A third confirmatory PSA measure is required (2nd beyond the reference level) to be greater than the second measure, and it must be obtained at least 7 days after the 2nd measure. If this is not the case, a fourth PSA is required to be taken and be greater than the second measure. The subject must have a PSA ≥ 5 ng/ml in addition to increasing PSA to be eligible. No minimum PSA is required for subjects with measurable disease or non-PSA evaluable disease.
- All subjects must have had a CT scan of the abdomen and pelvis within 84 days (12 weeks) prior to enrollment.
- All subjects must also have had a bone scan within 112 days (16 weeks) prior to enrollment.
- Subjects must have been surgically or medically castrated. If method of castration is LHRH agonists (leuprolide or goserelin), then the subject should be willing to continue the use of LHRH agonists. Castration using LHRH agonist should not be interrupted and subjects who have stopped treatment should be willing to restart.
- If the subject has been treated with non-steroidal anti-androgens (flutamide, bicalutamide, nilutamide or ketoconazole), they must have been stopped at least 28 days prior to enrollment for flutamide or ketoconazole and at least 42 days prior to enrollment for bicalutamide or nilutamide and the subjects must have demonstrated progression.
- Subjects may have received prior surgery. However, at least 21 days must have elapsed since completion of surgery and subject must have recovered from all side effects.
- All subjects must have pre-study PSA within 28 days of enrollment.
Subjects must meet the following initial laboratory criteria:
- granulocytes ≥ 1500/ul
- platelet count ≥ 100,000/ul
- hemoglobin ≥ 10 gms/dl
- bilirubin ≤ 1.5 x ULN
- AST ≤ 1.5 x ULN
- Creatinine ≤ 1.5 x ULN
- Testosterone < 50ng/ml for those who have not had bilateral orchiectomy
- PSA ≥ 5ng/ml if no measurable disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00061035
United States, California | |
University of California, San Diego Cancer Center | |
San Diego, California, United States, 92093-0987 |
Principal Investigator: | Frederick E. Millard, M.D | Associate Professor of Medicine at UCSD and Medical Director of the CTO of the UCSD Cancer Center |
Publications:
ClinicalTrials.gov Identifier: | NCT00061035 |
Obsolete Identifiers: | NCT00066261 |
Other Study ID Numbers: |
TLI-CA-TRT-001 |
First Posted: | May 22, 2003 Key Record Dates |
Last Update Posted: | August 28, 2008 |
Last Verified: | August 2008 |
Prostate Cancer; Immunotherapy |
Adenocarcinoma Prostatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Genital Neoplasms, Male |
Urogenital Neoplasms Neoplasms by Site Prostatic Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |